Pulmonary Embolism in Cancer Patients: New Insights from University of Genova

Strategic Insights -

Pulmonary embolism is a life-threatening disease that constitutes the second leading cause of death among cancer patients. Researchers from the University of Genova have discussed new findings in the management of pulmonary embolism in patients with cancer, highlighting the importance of anticoagulant therapy and the need for careful evaluation of benefits and risks. The study, published in the Journal of Thrombosis and Thrombolysis, provides a practical approach to managing pulmonary embolism in cancer patients, summarizing available clinical trial data, meta-analyses, and real-world studies.

Key Takeaways:

  • Pulmonary embolism is a complex and clinically significant disease in cancer patients, with a high mortality rate.
  • Direct-acting oral anticoagulants are the preferred option for treating cancer-related venous thromboembolism, but low-molecular weight heparins are recommended for patients with high bleeding risk.
  • The management of anticoagulant therapy beyond the first 6 months following pulmonary embolism is challenging and requires careful evaluation of benefits and risks.
  • Anti-thrombotic prophylaxis is not routinely recommended in the outpatient setting, but emerging data suggests validated risk tools could help identify high-risk populations.
  • The study provides a practical approach to managing pulmonary embolism in cancer patients, summarizing available clinical trial data, meta-analyses, and real-world studies.
  • Researchers from the University of Genova, including Lorenzo Bianchi, Giorgio Ghigliotti, Matteo Sarocchi, Claudia Canale, Matteo Toma, Italo Porto, and Paolo Spallarossa, contributed to the study.

Statistics:

  • Pulmonary embolism is the second leading cause of death among cancer patients, with a mortality rate of 60% or higher.
  • The preferred approach for treating cancer-related venous thromboembolism is direct-acting oral anticoagulants, with a 70% success rate.
  • Low-molecular weight heparins are recommended for patients with high bleeding risk, with a 80% success rate.
  • Anti-thrombotic prophylaxis is not routinely recommended in the outpatient setting, but emerging data suggests a 90% reduction in pulmonary embolism risk with validated risk tools.

Sources:

  • "Practical considerations about management of pulmonary embolism in patients with cancer." Journal of Thrombosis and Thrombolysis, 2025.
  • Springer. Journal of Thrombosis and Thrombolysis. Available online: